Vaccinex, Inc. is a privately held clinical-stage immunotherapy company engaged in the discovery and development of human therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases. The Company has completed phase 1 clinical trials in solid tumors and multiple sclerosis and is currently engaged in a phase 2 clinical trial in Huntington’s disease. Vaccinex utilizes its proprietary ActivMAb® Antibody Discovery Technology for rapid, mammalian cell-based antibody selection to build its antibody pipeline and in service to its biopharmaceutical partners.
ActivMAb® combines the advantages of rapid and sensitive selection by virus panning and cell sorting in one technology, with intrinsic selection of antibodies that are efficiently expressed in mammalian cells and have desirable solubility and stability properties. Vaccinex is based in Rochester, New York, USA.
State of Ownership
Business Development Executive, Nature Publishing Group, Springer Nature
Sales Account Executive, Springer Nature
Director of Sales , SOLABS
Medical doctor at National and Kapodistrian University of Athens, National and Kapodistrian University of Athens
Sr Business Development Manager at Eurofarma, Eurofarma
Former Head of Communities, Springer Nature
Managing Director, Thoroughly Good Consulting
Global Manager, Business Development, Nature Publishing Group
CEO & Co-Founder, Zapnito